HS-10566 for high-risk non-muscle-invasive bladder cancer when bladder removal is not an option

Trial details

Who runs it

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Trial code

NCT07468851

Record updated

4 September 2026

Original description

This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder cancer who are ineligible for or refuse radical cystectomy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.Read full original descriptionShow less

A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder cancer who are ineligible for or refuse radical cystectomy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.

Inclusion: Men or women aged greater than or equal to (≥) 18 years; Signed informed consent form; Histologically confirmed non-muscle-invasive bladder urothelial carcinoma (i.e., transitional cell carcinoma). Mixed tumor types predominantly consisting of urothelial carcinoma are eligible. Patients diagnosed with neuroendocrine, micropapillary, signet-ring cell, plasmacytoid, or sarcomatoid features are excluded; Patients with non-muscle-invasive bladder cancer (NMIBC) who have undergone prior transurethral resection of bladder tumor (TURBT) and who refuse or are ineligible for radical cystectomy, and meet one of the following two populations:; Patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy after prior TURBT, and who refuse or are ineligible for radical cystectomy. BCG unresponsive is defined as occurrence of any one of the following in NMIBC patients after adequate BCG therapy (at least 5 full dose inductions and at least 2 maintenance instillations of BCG):; Persistent or recurrent CIS within 12 months after adequate BCG therapy, with or without recurrence of high-grade Ta or T1 tumors; Recurrence of high-grade Ta/T1 tumors within 6 months after adequate BCG therapy; Recurrence of high-grade T1 tumors at the first assessment during maintenance therapy after BCG induction; Patients who have not received BCG therapy after prior TURBT, including the following three scenarios:; NMIBC patients who failed intravesical chemotherapy, and who have not received BCG; HR-NMIBC patients who have not received BCG therapy after TURBT; HR-NMIBC patients who received prior BCG therapy but discontinued treatment for more than 3 years before enrollment; Participants must have undergone TURBT within 12 weeks prior to signing informed consent and meet the following criteria:; For papillary lesions (Ta and T1 stages): complete resection of all visible papillary lesions, with negative urine cytology (including atypical findings); For patients with CIS: residual unresectable CIS lesions are permitted; Sufficient bone marrow reserve and adequate hepatic/renal function; Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.

Exclusion: Has received or is receiving any of the following treatments:; Regular intravesical chemotherapy (gemcitabine, pirarubicin, mitomycin, etc.) or BCG instillation intolerance following TURBT/bladder biopsy before enrollment; Pelvic radiotherapy within 4 weeks prior to first study treatment. Patients with last radiotherapy >4 weeks prior and no confirmed radiation cystitis may be enrolled; Major surgery (TURBT is not considered major surgery) within 4 weeks before first study treatment, or incomplete recovery from postoperative complications; Systemic chemotherapy, small-molecule targeted therapy, or investigational therapy within 4 weeks before first study treatment; Device-assisted chemotherapy (e.g. TAR-200); Residual toxicity ≥ Grade 2 per CTCAE version 6.0 from prior therapy (surgery, intravesical instillation, etc.), except alopecia, pigmentation; Bladder or urethral anatomical features that may interfere with HS-10566 implantation, retention, or removal (e.g., urethral stricture, bladder diverticulum, total urinary incontinence, bladder perforation); Current or history of clinically significant polyuria (24-hour urine output >4000 mL); Urothelial carcinoma outside the bladder (e.g., urethra, ureter, renal pelvis) unless radically resected with no disease recurrence for > 2 years; History of other primary solid tumors, except:; Radically treated solid tumor with no activity for ≥5 years before enrollment and low recurrence risk; adequately treated non-melanoma skin cancer (e.g., basal cell carcinoma, squamous cell carcinoma) or lentigo maligna with no evidence of recurrence; adequately treated carcinoma in situ (e.g., cervical, ductal carcinoma in situ of breast) with no evidence of recurrence; Histopathologically confirmed muscle invasive (pathologic T stage ≥ T2), locally advanced, unresectable, or metastatic urothelial carcinoma; Requirement for long-term indwelling urinary catheter during study treatment (e.g., urinary obstruction); Intermittent catheterization for clinical indications is allowed.

ClinicalTrials.gov NCT07468851